Latest Denosumab Stories
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
THOUSAND OAKS, Calif., Aug.
THOUSAND OAKS, Calif.
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
Advisory Committee to Review Denosumab Data THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S.
Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018...
New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...
National Osteoporosis Foundation's 8th International Symposium April 1-5, 2009 at Marriott Wardman Park Hotel WASHINGTON, March 19 /PRNewswire-USNewswire/ -- The National Osteoporosis Foundation (NOF) will bring together a faculty of internationally-renowned experts to share clinically relevant evidence-based information on bone health and osteoporosis prevention, diagnosis and treatment with hundreds of healthcare professionals at its comprehensive annual five-day conference in Washington, DC.
THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor.
THOUSAND OAKS, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.